The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer
Immune cell therapy as a revolutionary treatment modality, significantly transformed cancer care. It is a specialized form of immunotherapy that utilizes living immune cells as therapeutic reagents for the treatment of cancer. Unlike traditional drugs, cell therapies are considered “living drugs,” a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-03-01
|
| Series: | Cell Transplantation |
| Online Access: | https://doi.org/10.1177/09636897241231892 |
| _version_ | 1797278329664962560 |
|---|---|
| author | Jia Han Bowen Zhang Senyu Zheng Yuan Jiang Xiaopeng Zhang Kaiyun Mao |
| author_facet | Jia Han Bowen Zhang Senyu Zheng Yuan Jiang Xiaopeng Zhang Kaiyun Mao |
| author_sort | Jia Han |
| collection | DOAJ |
| description | Immune cell therapy as a revolutionary treatment modality, significantly transformed cancer care. It is a specialized form of immunotherapy that utilizes living immune cells as therapeutic reagents for the treatment of cancer. Unlike traditional drugs, cell therapies are considered “living drugs,” and these products are currently customized and require advanced manufacturing techniques. Although chimeric antigen receptor (CAR)-T cell therapies have received tremendous attention in the industry regarding the treatment of hematologic malignancies, their effectiveness in treating solid tumors is often restricted, leading to the emergence of alternative immune cell therapies. Tumor-infiltrating lymphocytes (TIL) cell therapy, cytokine-induced killer (CIK) cell therapy, dendritic cell (DC) vaccines, and DC/CIK cell therapy are designed to use the body’s natural defense mechanisms to target and eliminate cancer cells, and usually have fewer side effects or risks. On the other hand, cell therapies, such as chimeric antigen receptor-T (CAR-T) cell, T cell receptor (TCR)-T, chimeric antigen receptor-natural killer (CAR-NK), or CAR-macrophages (CAR-M) typically utilize either autologous stem cells, allogeneic or xenogeneic cells, or genetically modified cells, which require higher levels of manipulation and are considered high risk. These high-risk cell therapies typically hold special characteristics in tumor targeting and signal transduction, triggering new anti-tumor immune responses. Recently, significant advances have been achieved in both basic and clinical researches on anti-tumor mechanisms, cell therapy product designs, and technological innovations. With swift technological integration and a high innovation landscape, key future development directions have emerged. To meet the demands of cell therapy technological advancements in treating cancer, we comprehensively and systematically investigate the technological innovation and clinical progress of immune cell therapies in this study. Based on the therapeutic mechanisms and methodological features of immune cell therapies, we analyzed the main technical advantages and clinical transformation risks associated with these therapies. We also analyzed and forecasted the application prospects, providing references for relevant enterprises with the necessary information to make informed decisions regarding their R&D direction selection. |
| first_indexed | 2024-03-07T16:01:41Z |
| format | Article |
| id | doaj.art-0edf4bbd67ce4db2862d353f4ce55cbb |
| institution | Directory Open Access Journal |
| issn | 1555-3892 |
| language | English |
| last_indexed | 2024-03-07T16:01:41Z |
| publishDate | 2024-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cell Transplantation |
| spelling | doaj.art-0edf4bbd67ce4db2862d353f4ce55cbb2024-03-04T19:03:24ZengSAGE PublishingCell Transplantation1555-38922024-03-013310.1177/09636897241231892The Progress and Prospects of Immune Cell Therapy for the Treatment of CancerJia Han0Bowen Zhang1Senyu Zheng2Yuan Jiang3Xiaopeng Zhang4Kaiyun Mao5Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, ChinaShanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, ChinaSchool of Natural and Computing Sciences, University of Aberdeen, Aberdeen, UKShanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, ChinaShanghai World Trade Organization Affairs Consultation Center, Shanghai, ChinaShanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, ChinaImmune cell therapy as a revolutionary treatment modality, significantly transformed cancer care. It is a specialized form of immunotherapy that utilizes living immune cells as therapeutic reagents for the treatment of cancer. Unlike traditional drugs, cell therapies are considered “living drugs,” and these products are currently customized and require advanced manufacturing techniques. Although chimeric antigen receptor (CAR)-T cell therapies have received tremendous attention in the industry regarding the treatment of hematologic malignancies, their effectiveness in treating solid tumors is often restricted, leading to the emergence of alternative immune cell therapies. Tumor-infiltrating lymphocytes (TIL) cell therapy, cytokine-induced killer (CIK) cell therapy, dendritic cell (DC) vaccines, and DC/CIK cell therapy are designed to use the body’s natural defense mechanisms to target and eliminate cancer cells, and usually have fewer side effects or risks. On the other hand, cell therapies, such as chimeric antigen receptor-T (CAR-T) cell, T cell receptor (TCR)-T, chimeric antigen receptor-natural killer (CAR-NK), or CAR-macrophages (CAR-M) typically utilize either autologous stem cells, allogeneic or xenogeneic cells, or genetically modified cells, which require higher levels of manipulation and are considered high risk. These high-risk cell therapies typically hold special characteristics in tumor targeting and signal transduction, triggering new anti-tumor immune responses. Recently, significant advances have been achieved in both basic and clinical researches on anti-tumor mechanisms, cell therapy product designs, and technological innovations. With swift technological integration and a high innovation landscape, key future development directions have emerged. To meet the demands of cell therapy technological advancements in treating cancer, we comprehensively and systematically investigate the technological innovation and clinical progress of immune cell therapies in this study. Based on the therapeutic mechanisms and methodological features of immune cell therapies, we analyzed the main technical advantages and clinical transformation risks associated with these therapies. We also analyzed and forecasted the application prospects, providing references for relevant enterprises with the necessary information to make informed decisions regarding their R&D direction selection.https://doi.org/10.1177/09636897241231892 |
| spellingShingle | Jia Han Bowen Zhang Senyu Zheng Yuan Jiang Xiaopeng Zhang Kaiyun Mao The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer Cell Transplantation |
| title | The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer |
| title_full | The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer |
| title_fullStr | The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer |
| title_full_unstemmed | The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer |
| title_short | The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer |
| title_sort | progress and prospects of immune cell therapy for the treatment of cancer |
| url | https://doi.org/10.1177/09636897241231892 |
| work_keys_str_mv | AT jiahan theprogressandprospectsofimmunecelltherapyforthetreatmentofcancer AT bowenzhang theprogressandprospectsofimmunecelltherapyforthetreatmentofcancer AT senyuzheng theprogressandprospectsofimmunecelltherapyforthetreatmentofcancer AT yuanjiang theprogressandprospectsofimmunecelltherapyforthetreatmentofcancer AT xiaopengzhang theprogressandprospectsofimmunecelltherapyforthetreatmentofcancer AT kaiyunmao theprogressandprospectsofimmunecelltherapyforthetreatmentofcancer AT jiahan progressandprospectsofimmunecelltherapyforthetreatmentofcancer AT bowenzhang progressandprospectsofimmunecelltherapyforthetreatmentofcancer AT senyuzheng progressandprospectsofimmunecelltherapyforthetreatmentofcancer AT yuanjiang progressandprospectsofimmunecelltherapyforthetreatmentofcancer AT xiaopengzhang progressandprospectsofimmunecelltherapyforthetreatmentofcancer AT kaiyunmao progressandprospectsofimmunecelltherapyforthetreatmentofcancer |